Finally, the validation of the differential expression of PARP1 in p190+ ALL patient samples is attested when looking both into our molecular profile analysis and into online patient sample datasets (Figure 8), corroborating with the translational character of our study and reinforcing the potential of PARP1 as a biomarker in this subset of patients. Here, PARP1 is linked to acute lymphoblastic leukemia.